Tizanidine Tablet
Product Images NDC 85534-0029

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 85534-0029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hawaii Repack, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Fig1)

This text provides information about plasma Tzanidine concentration based on the different dosing scenarios (with food or without food) for 4 mg Tzanidine tablets and capsules. The concentrations are measured in ng/mL over time (hours from dosing). The text indicates different dosing regimens for tablets and capsules, along with a reference at the bottom of the page.*

FDA Label Image

Fig2 (Fig2)

This text provides information about the improvement in Ashworth Score after taking 16 mg of tizanidine compared to placebo over hours post-dose.*

FDA Label Image

Fig3 (Fig3)

This text discusses the improvement in the Ashworth Score due to treatment with Zanidine at a mean dose of 28.6 mg. The evaluation was done at the End of Maintenance Endpoint during Study Week 7 using the Last Observation Carried Forward method.*

FDA Label Image

2 (Label 2mg)

FDA Label Image

4 (Label 4mg)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.